Validation
| Gene Symbol | Curated Descriptions | Cell Lines | Isolations | Validations | Control-case | Tumor Stage & Subtype | Clinical Use | PMID |
|---|---|---|---|---|---|---|---|---|
| hsa-miR-20b-5p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-miR-29b-3p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-miR-338-3p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-miR-340-5p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-miR-486-5p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence-16 breast cancer patients without recurrence | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-miR-93-5p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-let-7a | Hsa-let-7a might be considered as a respectable diagnostic tool for monitoring of breast cancer patients | centrifugation ultracentrifugation and filtration or with the Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) | electron microscopy,nanoparticle tracking analysis,and western blot | 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) | ER+/-,PR+/-,HER2+/- stages II, III breast cancer | 27608715 | ||
| hsa-miR-122 | Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer | ultracentrifugation, Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) | electron microscopy,nanoparticle tracking analysis,and western blot | 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) | ER+/-,PR+/-,HER2+/- stages II, III breast cancer | 27608715 | ||
| hsa-miR-1246 | Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer | ultracentrifugation, Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) | electron microscopy,nanoparticle tracking analysis,and western blot | 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) | ER+/-,PR+/-,HER2+/- stages II, III breast cancer | 27608715 | ||
| hsa-miR-21 | Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer | centrifugation ultracentrifugation and filtration or with the Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) | electron microscopy,nanoparticle tracking analysis,and western blot | 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) | ER+/-,PR+/-,HER2+/- stages II, III breast cancer | 27608715 |